Navigation Links
New England Biolabs Receives Award to Develop Novel Enzymatic Reagents for Epigenetic Studies
Date:9/15/2010

IPSWICH, Mass., Sept. 15 /PRNewswire/ -- New England Biolabs (NEB) has announced that it has received fast track SBIR funding of $1.22 million to fund the research and development of novel enzymatic reagents for epigenetic studies.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090921/NE79207LOGO-b)

New England Biolabs is committed to developing tools that advance epigenetics research and discovery, and offers a growing range of products for use in this area. Scientists at NEB recently identified the MspJI family of restriction enzymes and demonstrated their utility in mapping epigenetic modifications. This family of enzymes has the ability to cleave out small fragments of DNA for use in applications such as next generation sequencing, as well as to identify 5-hydroxymethylcytosine* modifications, when used in conjunction with T4 B-glucosyltransferase. Funding will go towards continuing this work, simplifying the study of epigenetic DNA modifications and expanding their potential as biomarkers.

"The discovery of MspJI and its homologs offers a significant opportunity for greatly expanding the role of restriction enzymes in epigenetics research," states Dr. Richard Roberts, Chief Scientific Officer at New England Biolabs. "The use of MspJI and other restriction enzymes in this family will simplify the study of DNA methylation and will accelerate our understanding of the role of 5-hydroxymethylcytosine in the epigenome."

About NEB

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.

* In addition to 5-methylcytosine (5-mC), 5-hydroxymethylcytosine (5-hmC) modifications have been identified in genomic DNAs. The biological role of 5-hmC with respect to epigenetic changes is not currently understood.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
3. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
6. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
7. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
8. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
11. Diamyd(R) Study Published in Prestigious New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... Ontario , Feb. 16, 2017  Aralez Pharmaceuticals ... global specialty pharmaceutical company, today announced that executive management ... Conference to be held February 22-23, 2017. Adrian ... of the Company at 1:35 p.m. local time on ... and audio archive for the event may be accessed ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that Vincent J. Angotti ... a member of the company,s board of directors, ... over two decades of experience leading executive and ...
Breaking Medicine Technology:
(Date:2/18/2017)... CA (PRWEB) , ... February 18, 2017 , ... ... paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 ... and so many other applications. Users can pick and choose from hand-crafted ...
(Date:2/17/2017)... Davidson, NC (PRWEB) , ... February 17, 2017 , ... ... Davidson Commons Shopping Center in Davidson, NC. Dr. Brian Seese leads the practice as ... of dental services under one roof. Smiles by Seese serves patients of all ages ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare ... designed to further positively impact the health and wellness of our community in ... it our duty to seriously consider releasing our assets beyond our 5% targeted ...
(Date:2/17/2017)... Nashville, TN (PRWEB) , ... February 17, 2017 ... ... Services, Inc. (ISTS) brings its educational assistance management solution to the exhibit floor ... Convention Center in Orlando, Fla. , From Feb. 19–23, 2017, more than ...
(Date:2/17/2017)... Verdes, CA (PRWEB) , ... February 17, 2017 ... ... emotional flow is Dr. Carol Francis' goals for each and every ... Conference, Dr. Carol Francis will demonstrate five different brainwave tools which help energize ...
Breaking Medicine News(10 mins):